CL2015002372A1 - Un proceso para preparar un compuesto de fórmula (2-g) y (2-h) que comprende llevar a cabo la reducción enantioselectiva para obtener un compuesto de fórmula (3-c). un proceso para preparar un compuesto de fórmula (5-f). un proceso para preparar un compuesto de fórmula (m). - Google Patents

Un proceso para preparar un compuesto de fórmula (2-g) y (2-h) que comprende llevar a cabo la reducción enantioselectiva para obtener un compuesto de fórmula (3-c). un proceso para preparar un compuesto de fórmula (5-f). un proceso para preparar un compuesto de fórmula (m).

Info

Publication number
CL2015002372A1
CL2015002372A1 CL2015002372A CL2015002372A CL2015002372A1 CL 2015002372 A1 CL2015002372 A1 CL 2015002372A1 CL 2015002372 A CL2015002372 A CL 2015002372A CL 2015002372 A CL2015002372 A CL 2015002372A CL 2015002372 A1 CL2015002372 A1 CL 2015002372A1
Authority
CL
Chile
Prior art keywords
compound
formula
prepare
preparing
comprises carrying
Prior art date
Application number
CL2015002372A
Other languages
English (en)
Inventor
Robert Bruce Diebold
Thomas Gero
Paul Grover
Shan Huang
Stephanos Ioannidis
Claude Afona Ogoe
Jamal Carlos Saeh
Jeffrey Gilbert Varnes
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44528349&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2015002372(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of CL2015002372A1 publication Critical patent/CL2015002372A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/59—Hydrogenated pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6509—Six-membered rings
    • C07F9/650952—Six-membered rings having the nitrogen atoms in the positions 1 and 4

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

UN PROCESO PARA PREPARAR UN COMPUESTO DE FÓRMULA (2-G) Y (2-H) QUE COMPRENDE LLEVAR A CABO LA REDUCCIÓN ENANTIOSELECTIVA PARA OBTENER UN COMPUESTO DE FÓRMULA (3-C). UN PROCESO PARA PREPARAR UN COMPUESTO DE FÓRMULA (5-F). UN PROCESO PARA PREPARAR UN COMPUESTO DE FÓRMULA (M).
CL2015002372A 2010-08-06 2015-08-25 Un proceso para preparar un compuesto de fórmula (2-g) y (2-h) que comprende llevar a cabo la reducción enantioselectiva para obtener un compuesto de fórmula (3-c). un proceso para preparar un compuesto de fórmula (5-f). un proceso para preparar un compuesto de fórmula (m). CL2015002372A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37164810P 2010-08-06 2010-08-06
US38417010P 2010-09-17 2010-09-17

Publications (1)

Publication Number Publication Date
CL2015002372A1 true CL2015002372A1 (es) 2016-02-05

Family

ID=44528349

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2013000322A CL2013000322A1 (es) 2010-08-06 2013-01-31 Compuestos derivados de piperidina sustituida; proceso de preparacion; composicion farmaceutica y su uso para producir un efecto antiproliferativo y/o proapoptotico.
CL2015002372A CL2015002372A1 (es) 2010-08-06 2015-08-25 Un proceso para preparar un compuesto de fórmula (2-g) y (2-h) que comprende llevar a cabo la reducción enantioselectiva para obtener un compuesto de fórmula (3-c). un proceso para preparar un compuesto de fórmula (5-f). un proceso para preparar un compuesto de fórmula (m).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CL2013000322A CL2013000322A1 (es) 2010-08-06 2013-01-31 Compuestos derivados de piperidina sustituida; proceso de preparacion; composicion farmaceutica y su uso para producir un efecto antiproliferativo y/o proapoptotico.

Country Status (40)

Country Link
US (4) US20130310344A1 (es)
EP (1) EP2601177B1 (es)
JP (2) JP5886855B2 (es)
KR (1) KR101840893B1 (es)
CN (2) CN103153954B (es)
AR (1) AR082573A1 (es)
AU (2) AU2011287398C1 (es)
BR (1) BR112013002914B1 (es)
CA (1) CA2806190C (es)
CL (2) CL2013000322A1 (es)
CO (1) CO6670585A2 (es)
CR (1) CR20130051A (es)
CU (1) CU20130020A7 (es)
CY (1) CY1120031T1 (es)
DK (1) DK2601177T3 (es)
EA (1) EA027788B1 (es)
EC (1) ECSP13012426A (es)
ES (1) ES2653936T3 (es)
GT (1) GT201300034A (es)
HK (1) HK1220967A1 (es)
HR (1) HRP20171899T1 (es)
HU (1) HUE035254T2 (es)
IL (1) IL224218A (es)
LT (1) LT2601177T (es)
ME (1) ME02885B (es)
MX (1) MX343043B (es)
MY (1) MY165624A (es)
NI (1) NI201300018A (es)
NO (1) NO2601177T3 (es)
NZ (1) NZ607794A (es)
PL (1) PL2601177T3 (es)
PT (1) PT2601177T (es)
RS (1) RS56670B1 (es)
SA (1) SA111320683B1 (es)
SG (2) SG187178A1 (es)
SI (1) SI2601177T1 (es)
TW (1) TWI535712B (es)
UA (1) UA110943C2 (es)
UY (1) UY33547A (es)
WO (1) WO2012017251A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI535712B (zh) * 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
CA2897055C (en) 2013-01-16 2021-04-20 The Regents Of The University Of Michigan Substituted 2-(trifluoromethylsulfonyl)phenylamino compounds and pharmaceutical compositions thereof as bcl-2/bcl-xl inhibitors and therapeutic methods using the same
AU2015211021B2 (en) 2014-01-28 2020-07-02 Buck Institute For Research On Aging Methods and compositions for killing senescent cells and for treating senescence-associated diseases and disorders
US10328058B2 (en) 2014-01-28 2019-06-25 Mayo Foundation For Medical Education And Research Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques
US20170216286A1 (en) 2014-01-28 2017-08-03 Mayo Foundation For Medical Education And Research Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid
KR20170047397A (ko) 2014-09-10 2017-05-04 에피자임, 인코포레이티드 치환된 피페리딘 화합물
EP3689910A3 (en) 2014-09-23 2020-12-02 F. Hoffmann-La Roche AG Method of using anti-cd79b immunoconjugates
US11111259B2 (en) * 2015-12-18 2021-09-07 Unity Biotechnology, Inc. Acylsulfonamide derivatives for treating senescence-associated diseases and disorders
RU2020121147A (ru) 2016-03-28 2021-11-03 Пресидж Байосайенсиз, Инк. Фармацевтические комбинации для лечения злокачественной опухоли
JOP20190191A1 (ar) * 2017-02-22 2019-08-08 Astrazeneca Ab وحدات شجرية علاجية
US20200354336A9 (en) 2017-08-11 2020-11-12 Unity Biotechnology, Inc. Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells
US10588916B2 (en) 2017-10-31 2020-03-17 Unity Biotechnology, Inc. Technology to inhibit vascular changes that lead to vision loss in the eye
US10689416B2 (en) 2017-12-30 2020-06-23 Unity Biotechnology, Inc. Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer
JP2021510163A (ja) 2018-01-10 2021-04-15 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー ベンズアミド化合物
BR112020022092A2 (pt) 2018-04-29 2021-02-02 Beigene, Ltd. compostos, método para tratar doenças apoptóticas desreguladas e composição farmacêutica
CN117866015A (zh) 2018-04-30 2024-04-12 联合生物科技公司 一种临床管理中使用的化合物及其用途
CA3056878C (en) 2018-04-30 2021-03-30 Unity Biotechnology Phospholidines that are bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
US10738042B2 (en) 2018-04-30 2020-08-11 Unity Biotechnology, Inc. Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
US10717722B2 (en) 2018-06-13 2020-07-21 Unity Biotechnology, Inc. Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
US11491168B2 (en) 2018-07-31 2022-11-08 Ascentage Pharma (Suzhou) Co., Ltd. Combination of Bcl-2/Bcl-xL inhibitors and chemotherapeutic agent and use thereof
TW202021575A (zh) * 2018-08-17 2020-06-16 瑞典商阿斯特捷利康公司 樹枝狀體配製物
TWI831817B (zh) * 2018-08-17 2024-02-11 瑞典商阿斯特捷利康公司 治療癌症之方法
WO2020041406A1 (en) 2018-08-22 2020-02-27 Newave Pharmaceutical Inc. Bcl-2 inhibitors
US20220073513A1 (en) 2018-12-29 2022-03-10 Newave Pharmaceutical Inc. 1h-pyrrolo[2,3-b]pyridine derivatives and related compounds as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
WO2021066873A1 (en) 2019-10-03 2021-04-08 Newave Pharmaceutical Inc. Condensed heterocycles as bcl-2 inhibitors
WO2021133817A1 (en) 2019-12-27 2021-07-01 Guangzhou Lupeng Pharmaceutical Company Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
CN111537654B (zh) * 2020-07-07 2020-11-10 上海亚盛医药科技有限公司 N-(苯基磺酰基)苯甲酰胺化合物的hplc分析方法
BR112023000320A2 (pt) 2020-07-10 2023-01-31 Jiangsu Hengrui Pharmaceuticals Co Ltd Derivado de sulfonilbenzamida e seu cojugado, método de preparação do mesmo e seu uso
JP2023538695A (ja) 2020-08-25 2023-09-08 上海森輝医薬有限公司 薬剤を担持する高分子及びその調製方法
CN117642157A (zh) 2021-03-19 2024-03-01 伊尔治疗学股份有限公司 具有((3-硝基苯基)磺酰基)乙酰胺作为bcl-2抑制剂的化合物
CA3214042A1 (en) 2021-04-05 2022-10-13 Halia Therapeutics, Inc. Nek7 inhibitors
WO2022226182A1 (en) 2021-04-22 2022-10-27 Halia Therapeutics, Inc. Nek7 inhibitors
CN113248415B (zh) * 2021-05-26 2022-08-09 苏州正永生物医药有限公司 一种abt-737关键中间体的制备方法以及abt-737的制备方法
WO2024059200A1 (en) 2022-09-14 2024-03-21 Halia Therapeutics, Inc. Nek7 inhibitors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
EP0880508B1 (en) 1996-02-13 2003-04-16 AstraZeneca AB Quinazoline derivatives as vegf inhibitors
ATE211134T1 (de) 1996-03-05 2002-01-15 4-anilinochinazolin derivate
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
ATE482946T1 (de) 1999-02-10 2010-10-15 Astrazeneca Ab Chinazolinderivate als angiogenesehemmer und zwischenprodukte dafür
KR20030013433A (ko) 2000-05-31 2003-02-14 아스트라제네카 아베 혈관 손상 활성을 가진 인돌 유도체
UA73993C2 (uk) 2000-06-06 2005-10-17 Астразенека Аб Хіназолінові похідні для лікування пухлин та фармацевтична композиція
EE200300015A (et) 2000-07-07 2004-10-15 Angiogene Pharmaceuticals Limited Kolhinooli derivaadid kui angiogeneesi inhibiitorid
AU6623301A (en) 2000-07-07 2002-01-21 Angiogene Pharm Ltd Colchinol derivatives as vascular damaging agents
US6720338B2 (en) * 2000-09-20 2004-04-13 Abbott Laboratories N-acylsulfonamide apoptosis promoters
AR031130A1 (es) * 2000-09-20 2003-09-10 Abbott Lab N-acilsulfonamidas promotoras de la apoptosis
US7973161B2 (en) 2003-11-13 2011-07-05 Abbott Laboratories Apoptosis promoters
US8614318B2 (en) 2003-11-13 2013-12-24 Abbvie Inc. Apoptosis promoters
US7767684B2 (en) 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US7642260B2 (en) 2003-11-13 2010-01-05 Abbott Laboratories, Inc. Apoptosis promoters
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
AU2006297853B2 (en) 2005-05-12 2010-08-19 AbbVie Global Enterprises Ltd. Apoptosis promoters
NZ566208A (en) * 2005-08-11 2010-09-30 Vertex Pharma 2-Thiazolamide derivatives as modulators of cystic fibrosis transmembrane conductance regulators
CN101535280B (zh) * 2006-11-15 2012-06-27 健泰科生物技术公司 芳基磺酰胺化合物
ES2525716T3 (es) * 2007-06-27 2014-12-29 Astrazeneca Ab Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
WO2009036035A1 (en) * 2007-09-10 2009-03-19 Curis, Inc. Bcl-2 inhibitors
EP3666758A1 (en) * 2008-12-05 2020-06-17 AbbVie Inc. Process for the preparation of a sulfonamide derivative
DK2435432T6 (da) 2009-05-26 2023-12-18 Abbvie Ireland Unlimited Co Apoptose-inducerende midler til behandling af cancer og immune og autoimmune sygdomme
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
TWI540132B (zh) 2009-06-08 2016-07-01 亞培公司 Ｂｃｌ-２族群抑制劑之口服醫藥劑型
TWI535712B (zh) * 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物

Also Published As

Publication number Publication date
US9248140B2 (en) 2016-02-02
EA027788B1 (ru) 2017-09-29
CY1120031T1 (el) 2018-12-12
MX343043B (es) 2016-10-21
EP2601177A1 (en) 2013-06-12
MX2013001494A (es) 2013-03-18
IL224218A (en) 2016-07-31
LT2601177T (lt) 2017-12-27
CA2806190C (en) 2018-07-17
UA110943C2 (uk) 2016-03-10
GT201300034A (es) 2015-08-03
NZ607794A (en) 2015-03-27
AU2011287398A1 (en) 2013-03-07
UY33547A (es) 2012-03-30
CR20130051A (es) 2013-05-15
CU20130020A7 (es) 2013-07-31
US20150328239A1 (en) 2015-11-19
SG187178A1 (en) 2013-03-28
HUE035254T2 (en) 2018-05-02
US20120035134A1 (en) 2012-02-09
CA2806190A1 (en) 2012-02-09
TW201209049A (en) 2012-03-01
DK2601177T3 (en) 2018-01-02
BR112013002914A2 (pt) 2019-01-08
CO6670585A2 (es) 2013-05-15
AR082573A1 (es) 2012-12-19
CN105367482B (zh) 2017-12-12
RS56670B1 (sr) 2018-03-30
EP2601177B1 (en) 2017-10-18
ES2653936T3 (es) 2018-02-09
HK1220967A1 (zh) 2017-05-19
JP2016138109A (ja) 2016-08-04
KR20130137599A (ko) 2013-12-17
WO2012017251A1 (en) 2012-02-09
ME02885B (me) 2018-04-20
CN103153954A (zh) 2013-06-12
AU2011287398C1 (en) 2017-08-24
PL2601177T3 (pl) 2018-02-28
SA111320683B1 (ar) 2015-05-19
NO2601177T3 (es) 2018-03-17
AU2011287398B2 (en) 2015-08-27
JP2013532718A (ja) 2013-08-19
JP5886855B2 (ja) 2016-03-16
EA201300211A1 (ru) 2013-08-30
US20160176906A1 (en) 2016-06-23
BR112013002914B1 (pt) 2021-06-15
US9018381B2 (en) 2015-04-28
NI201300018A (es) 2013-10-16
SI2601177T1 (en) 2018-01-31
AU2015210452A1 (en) 2015-09-03
ECSP13012426A (es) 2013-03-28
US20130310344A1 (en) 2013-11-21
CN103153954B (zh) 2015-11-25
CN105367482A (zh) 2016-03-02
TWI535712B (zh) 2016-06-01
CL2013000322A1 (es) 2013-04-19
PT2601177T (pt) 2017-12-18
HRP20171899T1 (hr) 2018-01-26
SG10201506194YA (en) 2015-09-29
MY165624A (en) 2018-04-18
KR101840893B1 (ko) 2018-03-21

Similar Documents

Publication Publication Date Title
CL2015002372A1 (es) Un proceso para preparar un compuesto de fórmula (2-g) y (2-h) que comprende llevar a cabo la reducción enantioselectiva para obtener un compuesto de fórmula (3-c). un proceso para preparar un compuesto de fórmula (5-f). un proceso para preparar un compuesto de fórmula (m).
CL2012000590A1 (es) Proceso para preparar w-transaminasa (r)-selectiva.
CO7141404A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
EA201201288A1 (ru) Способ применения реактивов гриньяра
CR20150370A (es) Compuestos antivirales
CR20140534A (es) Proceso para la preparación de treprostinil y derivado de los mismos
MX2016017355A (es) Lipido que comprende acido docosapentaenoico.
BR112016029333A2 (pt) síntese de compostos de carbamoilpiridona policíclico
UY34697A (es) Métodos para preparar análogos de nucleótidos
EP3778606A3 (en) Condensed imidazolylimidazoles as antiviral compounds
CL2009000503A1 (es) Proceso de preparacion de compuestos derivados de acido 2-amino-5-cianobenzoico-3-sustituidos o 1h-pirazol-5-carboxamida.
CU24354B1 (es) Procedimiento de obtención de derivados de tetrafluoropropilmorfolina
MY163339A (en) A method of producing ingenol-3-angelate
MX2015002487A (es) Proceso para la preparacion de teneligliptina.
CL2012002082A1 (es) Proceso para la preparacion de lacosamida, por hidroximetilación; compuestos intermediarios.
UA111333C2 (uk) Спосіб одержання l-аргінінової солі периндроприлу
GEP201706626B (en) Synthesis of (s)-nifuratel
EA201491446A1 (ru) Способы получения пиперазинового пролекарства - ингибитора прикрепления вич
CO7141402A2 (es) Procesos para producir ciertos 2 (piridin 3 il)tiazoles
BR112015024859A2 (pt) processo e intermediários para a preparação de pregabalina
EA201590116A1 (ru) Способ получения замещенных триазолопиридинов
CR20110208A (es) Proceso para la preparación de benzonorbornenos
EA201500210A1 (ru) Способ переэтерификации эфиров ретинола
EA201391344A1 (ru) Способ увеличения расхода водной дисперсии
EP3239146A4 (en) Method for producing proton pump inhibitor compound having optical activity